Immunotherapy of chronic myeloid leukemia: present state and future prospects

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Buchdunger E, Cioffi CL, Law N et al.: Abl protein-tyrosine kinase inhibitor ST171 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther.295,137–145 (2000).
  Google Scholar
• 2  Druker BJ, Guilhot F, O’Brien SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355,2408–2417 (2006).▪ Summarizes the remarkable success of treatment of chronic myeloid leukemia (CML) with imatinib mesylate.
  Medline CASGoogle Scholar
• 3  Druker BJ, Sawyers C, Kantarjian H et al.: Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblasti leukemia with the Philadelphia chromosome. N. Engl. J. Med.344,1038–1042 (2001).
  Medline CASGoogle Scholar
• 4  le Coutre P, Tassi E, Varella-Garcia M et al.: Induction of resistence to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification. Blood95,1758–1766 (2000).
  Medline CASGoogle Scholar
• 5  Hochhaus A, Kreil S, Corbin AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia16,2190–2196 (2002).
  Medline CASGoogle Scholar
• 6  Azam M, Daley GQ: Anticipating clinical resistance to target-directed agents: the BCR–ABL paradigm. Mol. Diagn. Ther.10,67–76 (2006).
  Medline CASGoogle Scholar
• 7  Shah NP, Tran NP, Lee FY et al.: Overriding imatinib resistence with a novel ABL kinase inhibitor. Science305,399–401 (2004).
  Medline CASGoogle Scholar
• 8  Weisberg E, Manley PW, Breitenstrein W et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl. Cancer Cell7,129–141 (2005).
  Medline CASGoogle Scholar
• 9  Seggewiss R, Price DA, Purbhoo MA: Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy10,633–641 (2008).
  Medline CASGoogle Scholar
• 10  Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS: Peptides spanning the junctional region of both the bcr–abl fusion proteins bind common HLA class I molecules. Leukemia14,419–426 (2000).
  Medline CASGoogle Scholar
• 11  Pittet MJ: Behaviour of immune players in the tumor microienvirnoment. Curr. Opin. Oncol.21,2153–2159 (2009).
  Google Scholar
• 12  Stewart TJ, Abrams SI: How tumours escape mass destruction. Oncogene27,5894–5903 (2008).
  Medline CASGoogle Scholar
• 13  Bronte V, Mocellin S: Suppressive influences in the immune response to cancer. J. Immunother.32,1–11 (2009).
  MedlineGoogle Scholar
• 14  Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr–abl gene expression at a very low level in blood cells of some healthy individuals. Blood86,3118–3122 (1995).
  Medline CASGoogle Scholar
• 15  Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR–ABL fusion genes in leukocytes of normal individuals: biologic significance and implication for the assessment of minimal residual disease. Blood92,3362–3367 (1998).
  Medline CASGoogle Scholar
• 16  Posthuma EF, Falkenburg JH, Apperley JF et al.: HLA-B8 and HLA-A3 coexpressed with HLA B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBHT. Blood93,3863–3865 (1999).
  Medline CASGoogle Scholar
• 17  Khosravi F, Amirzargar A, Sarafnejad A et al : HLA class II allele and haplotype frequencies in Iranian patients with leukemia. Iran J. Allergy Asthma Immunol.6,137–142 (2007).
  MedlineGoogle Scholar
• 18  Naugler C, Liwski R: HLA risk markers for chronic myelogenous leukemia in eastern Canada. Leuk. Lymphoma50,254–259 (2009).
  MedlineGoogle Scholar
• 19  Chakrabarti D, Hultgren B, Stewart TA: IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J. Immunol.157,522–528 (1996).
  Medline CASGoogle Scholar
• 20  Molldrem JL, Lee PP, Wang C et al : Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med.6,1018–1023 (2000).
  Medline CASGoogle Scholar
• 21  Burchert A, Wolfl S, Schmidt M et al.: Interferon-α but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and specific T-cell response in chronic myeloid leukemia. Blood101,259–264 (2003).
  Medline CASGoogle Scholar
• 22  Gabriele L, Borghi P, Rozera C et al.: IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood103,980–987 (2004).
  Medline CASGoogle Scholar
• 23  Collins RH Jr, Spilberg O, Drobyski WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol.15,433–434 (1997).
  MedlineGoogle Scholar
• 24  Norde WJ, Overes IM, Maas F et al.: Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood113,2312–2323 (2009).
  Medline CASGoogle Scholar
• 25  Bocchia M, Wentworth PA, Southwood S et al.: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood85,2680–2684 (1995)
  Medline CASGoogle Scholar
• 26  Bocchia M, Korontsvit T, Xu Q et al: Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood87,3587–3592 (1996).
  Medline CASGoogle Scholar
• 27  ten Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC: Recognition of BCR–ABL positive leukemic blasts by human CD4⁺ T cells elicited by primary in vitro immunization with a BCR–ABL breakpoint peptides. Blood88,3522–3527 (1996)
  Medline CASGoogle Scholar
• 28  ten Bosch GJ, Toornvliet AC, Friede T, Melief CJ, Leeksma OC: Recognition of peptides corresponding to the joining region of p210BCR–ABL protein by human T cells. Leukemia9,1344–1348 (1995).
  Medline CASGoogle Scholar
• 29  Pawelec G, Max H, Halder T et al.: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found in low frequency in the repertoire of normal donors. Blood88,2118–2124 (1996).
  Medline CASGoogle Scholar
• 30  Osman Y, Takahashi M, Zheng Z et al.: Generation of bcr-abl-specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its application for donor leukocyte transfusions in marrow grafted CML patients. Leukemia13,166–174 (1999).
  Medline CASGoogle Scholar
• 31  Pinilla-Ibarz J, Cathcart K, Scheinberg DA: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev.14,11–20 (2000).
  Google Scholar
• 32  Yotnda P, Firat P, Garcia-Pons F et al.: Cytotoxic T cells response against the chimeric p210 BCR–ABL protein in patients with chronic myelogenous leukaemia. J. Clin. Invest.101,2290–2296, (1998).
  Medline CASGoogle Scholar
• 33  Clark RE, Dodi IA, Hill SC et al.: Direkt evidence that leukemic cells present HLA-associated immunogenic peptides derived from BCR–ABL b3a2 fusion protein. Blood98,2887–2893 (2001).
  Medline CASGoogle Scholar
• 34  Wagner WM, Ouyang Q, Pawelec G: The abl-bcr gene product as a novel leukemia specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4⁺ and CD8⁺ T lymphocytes. Cancer Immunol. Immunother.52,89–96 (2003).
  Medline CASGoogle Scholar
• 35  Gannagé M, Abel M, Michallet AS et al.: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol.174,8210–8218 (2005).
  Medline CASGoogle Scholar
• 36  El-Shami K, Smith BD: Immunotherapy for myeloid leukemias: current status and future directions. Leukemia22,1658–1664 (2008).
  Medline CASGoogle Scholar
• 37  Grünebach F, Mirakaj V, Mirakaj V, Miller MR, Brümmendorf T, Brossart P: BCR–ABL is not an immunodominant in chronic myeloid leukemia. Cancer Res.66,5892–5900 (2006)▪ Demonstrates convincing evidence that p210bcr–abl is not the immunodominant antigen in CML.
  Medline CASGoogle Scholar
• 38  Brauer KM, Werth D, von Schwarzenberg K et al.: BCR–ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res.67,5489–5497 (2007)▪ p210bcr–abl plays the critical role in aberrant expression of a number of cellular proteins.
  Medline CASGoogle Scholar
• 39  Scheich F, Duyster J, Peschel C, Bernhardt H: The immunogenicity of Bcr–Abl-expressing dendritic cells is dependent on the Bcr–Abl kinase activity and dominated by Bcr–Abl-regulated antigens. Blood110,2556–2560 (2007).
  Medline CASGoogle Scholar
• 40  Witko-Sarsat V, Canteloup S, Durant S et al.: Cleavage of p21waf1 by proteinase 3, a myeloid-specific serine protease, potentiates cell proliferation. J. Biol. Chem.277,47338–47347 (2002).
  Medline CASGoogle Scholar
• 41  El-Ouriaghli F, Sloand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ: Clonal dominance of chronic myelogenous leukaemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase Blood15,3786–3792 (2003).
  Google Scholar
• 42  Wilson TJ, Nannuru KC, Singh RK: Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1. Cancer Res.69,3186–3195 (2009).
  Google Scholar
• 43  Reed JC, Pelecchia M: Apoptosis-based therapies for hematologic malignancies. Blood106,408–418 (2005).
  Medline CASGoogle Scholar
• 44  Lam JS, Pantuc AJ, Belldegrun AS, Figlin RA: G 250: a carbonic anhydrase IX monoclonal antibody. Curr. Oncol. Rep.7,109–115 (2005).
  Medline CASGoogle Scholar
• 45  Beatty GL, Vonderheide RH: Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev. Vaccines7,881–887 (2008).
  Medline CASGoogle Scholar
• 46  Resto VA, Caballero OL, Buta MR et al.: A putative oncogenic role for MPP11 in head and neck squamous cell cancer. Cancer Res.60,5529–5535 (2000).
  Medline CASGoogle Scholar
• 47  Scanlan MJ, Simpson JG, Old LJ: The cancer/testis genes: review, standardization and commentary. Cancer Immunol.4,1–13 (2004).
  MedlineGoogle Scholar
• 48  Oehler VG, Guthrie KA, Cummings CL et al.: The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematotopoietic and leukemic progenitor cells. Blood114,3299–3308 (2009).
  Medline CASGoogle Scholar
• 49  van Baren N, Chambost H, Ferrant A et al.: PRAME, a gene encoding an antigen recognized in human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br. J. Haematol.102,1376–1379 (1998).
  Medline CASGoogle Scholar
• 50  Reiter R, Gais P, Jütting U et al.: Aurora-kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res.12,5136–5141 (2006).
  Medline CASGoogle Scholar
• 51  Yang XF, Wu CJ, Chen L et al.: CML 28 is broadly immunogenic antigen, which is expressed in tumor cells. Cancer Res.62,5517–5522 (2002).
  Medline CASGoogle Scholar
• 52  Wang Q, Li M, Wang YJ et al: RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of Hela cells. Cancer Lett.269,127–138 (2008).
  Medline CASGoogle Scholar
• 53  Schmidt SM, Schag K, Muller MR et al: Induction of adipophilin-specific cytotoxic lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res.64,1164–1170 (2004).
  Medline CASGoogle Scholar
• 54  Shin S, Sung BJ, Cho YS et al: An anti-apoptotic protein human survivin is direct inhibitor of caspase-3 and -7. Biochemistry40,1117–1123 (2001).
  Medline CASGoogle Scholar
• 55  Carter BZ, Mak DH, Schober WD et al: Regulation of survivin expression through Bcr–Abl/MARK cascade: targeting survivin overcomes imatinib resistence and increases imatinib sensitivity in imatinib-responsive CML cells. Blood107,1555–1563 (2006).
  Medline CASGoogle Scholar
• 56  Postel EH, Berberich SJ, Rooney JW, Kaetzel DM: Human NM23-H2 nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements. J. Bioenerg. Biomembr.32,277–284 (2000).
  Medline CASGoogle Scholar
• 57  Greiner J, Schmitt M: Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur. J. Haematol.80,461–468 (2008).
  MedlineGoogle Scholar
• 58  Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T cell exhaustion and disease progression. Blood114,1528–1536 (2009).
  Medline CASGoogle Scholar
• 59  Papallardo F, Pennisi M, Castiglione F, Motta S: Vaccine protocols optimization: in silico experiments. Biotechnol. Adv.28,82–93 (2100).
  Google Scholar
• 60  Gowthaman U, Agrewala JN: In silico methods for predicting the cell epitopes: Dr Jekyll or Mr Hyde? Expert Rev. Protomics6,527–537 (2010).
  Google Scholar
• 61  He L, Feng H, Raymond A et al: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother.50,31–40 (2001).
  Medline CASGoogle Scholar
• 62  Kislin KL, Marron MT, Li G, Graner MW, Katsanis E: Chaperone-rich cell lysate embedded with BCR–ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR–ABL positive leukemia. FASEB J.21,2173–2184 (2007).
  Medline CASGoogle Scholar
• 63  Krause DS, Van Etten RA: Adoptive immunotherapy of BCR–ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model Blood,104,4236–4244 (2004).
  Medline CASGoogle Scholar
• 64  Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB: Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene25,4483–4490 (2006).
  Medline CASGoogle Scholar
• 65  Deeb D, Gao X, Jiang H, Divine G, Dulchavsky SA, Gautam BC: Vaccination with leukemia-loaded dendritic cells eradicates residual diseases and prevent relapse. J. Exp. Ther. Oncol.5,183–193 (2006).
  Medline CASGoogle Scholar
• 66  McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature haematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl Acad. Sci USA84,6558–6562 (1987).
  Medline CASGoogle Scholar
• 67  Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukaemia-specific P210bcr/abl protein. Proc. Natl. Acd. Sci. USA85,9312–9316 (1988).
  Medline CASGoogle Scholar
• 68  Sobotková E, Ludvíková V, Petráčková M et al.: Characteristics of two mouse bcr-abl-transformed cell lines I. General properties of the cells. Folia Biol. (Praha)51,12–18 (2005).
  Medline CASGoogle Scholar
• 69  Jelínek F, Sobotková E, Vonka V: Characteristics of two mouse bcr-abl-transformed cell lines. II. Pathological lesions induced in mice. Folia Biol. (Praha)51,93–102 (2005).
  Medline CASGoogle Scholar
• 70  Lucanský V, Sobotková E, Tachezy R, Dušková M, Vonka V: DNA vaccination against bcr-abl-transfornmed cells in mice. Int. J. Oncol.35,941–951 (2009).▪ DNA fragment of the bcr–abl gene coding for the fusion zone of p210bcr–abl is not capable of uinducing protection against the challenge with bcr–abl-transformed cells in syngeneic Balb/c mice.
  Medline CASGoogle Scholar
• 71  Hrušková V, Morávková A, Babiarova K et al: Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles. Int. J. Oncol.35,1247–1256 (2009).▪ Polyomavirus-like-particles carrying a 171-amino-acid long fragment of the p210bcr–abl including its fusion zone, were not capable of inducing protection against the challenge with bcr–abl-transformed cells in syngeneic Balb/c mice.
  Medline CASGoogle Scholar
• 72  Petráčková M, Sobotková E, Dušková M, Jinoch P, Vonka V: Isolation and properties of gene-modified mouse bcr–abl-transformed cells expressing various immunostimulatory factors. Neoplasma56,194–201 (2009).
  Medline CASGoogle Scholar
• 73  Sobotková E, Dušková M, Tachezy R, Petrackova M, Vonka V: Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncol. Rep.21,793–799 (2009).▪ Combination of chemotherapy with vaccination with gene-modified bcr–abl-transformed had a marked therapeutic effect in mice inoculated with syngeneic bcr–abl-transformed cells.
  Medline CASGoogle Scholar
• 74  Orsini E, Calabrese E, Maggio R et al.: Circulating myeloid dendritic cells directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr–abl translocation. Leuk. Res.30,785–794 (2006).
  Medline CASGoogle Scholar
• 75  Mumprecht S, Claus C, Schürch CH, Pavelic V, Matter MS, Ochsenbein AF: Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood113,4681–4689 (2009).
  Medline CASGoogle Scholar
• 76  Humlová Z, Klamová H, Janatková I et al.: Immunological profiles of patients with chronic myeloid leukaemia I. State before the start of treatment. Folia Biol. Prague)52,47–58 (2006).
  Medline CASGoogle Scholar
• 77  Reuschenbach M, von Knebel-Doeberitz M, Wentzensen N: A systemic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother.58,1535–1544 (2009).
  Medline CASGoogle Scholar
• 78  De Gruijl TD, van der Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogenic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother.57,1569–1577 (2008).▪ Discusses the advantages and disadvantages of autologous and allogenic cell-based vaccines.
  MedlineGoogle Scholar
• 79  Michor F, Hughes TP, Iwasa Y et al.: Dynamics of chronic myeloid leukaemia Nature435,1267–1270 (2005).
  Medline CASGoogle Scholar
• 80  Abbott LH, Michor F: Mathematical models of targeted cancer therapy. Br. J. Cancer95,1136–1141 (2006).
  Medline CASGoogle Scholar
• 81  Graham SM, Jorgensen HG, Allan E et al.: Primitive quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia cells are insensitive to STI571 in vitro. Blood99,319–325 (2002).
  Medline CASGoogle Scholar
• 82  Roeder I, Horn M, Glauche I, Hochaus A, Mueller MC, Loeffler M: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications Nat. Med.12,1181–1184 (2006).
  Medline CASGoogle Scholar
• 83  Chávez-Gonzáles A, Ayala-Sánchez M, Sánchez-Valle E et al.: Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved haematological remission after different therapeutic procedures. Leuk. Res.30,286–295(2006).
  MedlineGoogle Scholar
• 84  Glauche I, Horn M, Roeder I: Leukemia stem cells: hit or miss? Br. J. Cancer96,677–678 (2007).
  Medline CASGoogle Scholar
• 85  Komarova NL, Wodarz D: Drug resistance in cancer. Principles of emergence and prevention. Proc. Natl Acad. Sci. USA102,9714–9719 (2005).
  Medline CASGoogle Scholar
• 86  Guo XY, Cuillerot T, Wang T et al.: Peptide containing the BCR oligomerization domain (AA 1–160) reverses the transformed phenotype of p210bcr–abl positive 32D myeloid leukemia cells. Oncogene17,825–833 (1998).
  Medline CASGoogle Scholar
• 87  Tolcher AW, Mita A, Lewis LD et al.: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol.26,5198–5203 (2008).
  Medline CASGoogle Scholar
• 88  Tolcher A: Targeting Bcl-2 protein expression in solid tumors and haematological malignancies with antisense oligonucleotides. Clin. Adv. Hematol. Oncol.3,635–642 (2005).
  MedlineGoogle Scholar
• 89  Jayanthan A, Howard SC, Trippett T et al.: Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk. Lymphoma50,1069–1072 (2009).
  MedlineGoogle Scholar
• 90  Ochi T, Fujiwara H, Suemori K et al.: Aurora-A kinase: a novel target of cellular immunotherapy for leukaemia. Blood113,66–74 (2008).
  MedlineGoogle Scholar
• 91  Chen CI, Maecker HT, Lee PP: Development and dynamics of robust T cell response to CML under imatinib treatment. Blood111,5342–5349 (2008).▪ Describes a strong but transitory immune response to CML cells in imatinib mesylate-treated patients.
  Medline CASGoogle Scholar
• 92  Kim PS, Lee PP, Levy D: Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol.4,E1000095 (2008).▪ Presents a mathematical model substantiating the concept that chemotherapy followed by immunotherapy may result in the cure of CML.
  MedlineGoogle Scholar
• 93  Pinilla-Ibarz J, Cathcart K, Korontsvit T et al.: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood95,1781–1787 (2000).
  Medline CASGoogle Scholar
• 94  Takahashi T, Tanaka Y, Nieda M et al.: Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk. Res.27,795–802 (2003).
  MedlineGoogle Scholar
• 95  Ossenkoppele GJ, Stam AG, Westers TM et al.: Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemia dendritic cells. Leukemia17,1424–1426 (2003).
  Medline CASGoogle Scholar
• 96  Heslop HE, Stevenson FK, Molldrem JJ: Immunotherapy of hematologic malignancy. Hematology Am. Soc. Hematol. Educ. Program331–349 (2003).
  MedlineGoogle Scholar
• 97  Cathcart K, Pinilla-Ibarz J, Korontsvit T et al.: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood103,1037–1042 (2004).
  Medline CASGoogle Scholar
• 98  Bocchia M, Gentili S, Abruzzese E et al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet365,657–662 (2005).
  Medline CASGoogle Scholar
• 99  Li Z, Qiao Y, Liu B et al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res.11,4460–4468 (2005).
  Medline CASGoogle Scholar
• 100  Rojas JM, Knight K, Wang L, Clark RE: Clinical evaluation of BCR–ABL peptide immunisation in chronic myeloid leukemia: results of the EPIC study. Leukemia21,2287–2295 (2007).
  Medline CASGoogle Scholar
• 101  Westermann J, Koop J, van Lessen A et al.: Vaccination with autologous non-irradiated dendritic cells in patients with bcr-abl⁺ chronic myeloid leukemia. Br. J. Hematol.137,297–306 (2007).
  Medline CASGoogle Scholar
• 102  Rezvani K, Yong AS, Mielke S et al : Leukemia-associated antigen-specific T cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111,236–242 (2008).
  Medline CASGoogle Scholar
• 103  Jain N, Reuben JM, Kantarjian H et al.: Synthetic tumor-specific breakpoint vaccine in patients with chronic myeloid leukaemia and minimal residual disease: a Phase 2 trial. Cancer115,3924–3934 (2009).
  MedlineGoogle Scholar
• 104  Maslak PG, Dao T, Gomez M et al.: A pilot vaccination trial of synthetic analog peptides derived from the BCR–ABL breakpoints in CML patients with minimal disease. Leukemia22,1613–1616 (2008).
  Medline CASGoogle Scholar
• 105  Bellantuono I, Gao L, Parry S et al: Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood100,3835–3837 (2002).
  Medline CASGoogle Scholar
• 106  Millerem JJ, Lee PP, Wang C, Champlin RE, Davis MM: A Pr1- human antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelologenous leukemia. Cancer Res.59,2675–2681 (1999).
  MedlineGoogle Scholar
• 107  Schmitt M, Li L, Giannopoulos K et al.: Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8⁺ T-cell responses and are lacking co-stimulatory molecules. Exp. Hematol.34,1709–1719 (2006).
  Medline CASGoogle Scholar
• 108  Yong AS, Keyvanfar K, Eniafe R et al.: Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukaemia-associated antigens: implications for the graft-versus-leukemia effects and peptide vaccine based immunotherapy. Leukemia22,1721–1727 (2008).
  Medline CASGoogle Scholar
• 109  Fujiwara H, Melenhorts JJ, Ouriaghli F et al.: In vitro induction of myeloid leukaemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin. Cancer Res.11,4495–4503 (2005).
  Medline CASGoogle Scholar
• 110  Adams SP, Sahota SS, Milovic A et al: Frequent expression of HAGE in presentation chronic myeloid leukemias. Leukemia16,2238–2242 (2002).
  Medline CASGoogle Scholar
• 111  Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees R: Tumour antigen-targeted immunotherapy for chronic myeloid leukemia: is it still viable? Cancer Immunol. Immunother.58,1489–1499 (2009).
  Medline CASGoogle Scholar
• 112  Rezvani K, Yong AS, Tawab A et al.: Ex vivo characterization of polyclonal memory CD8⁺ T cell responses to PRAME- specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood113,2245–2255 (2009).
  Medline CASGoogle Scholar
• 113  Kessler JH, Beekman NJ, Bres-Vloemans SA et al.: Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med.193,73–88 (2001).
  Medline CASGoogle Scholar
• 114  Quintarelli C, Dotti G, DeAngelis B et al.: Cytoxic T lymphocytes directed to the perefertially expressed antigen of melanoma (PRAME) target chronic myelod leukemia. Blood112,1876–1885 (2008).
  Medline CASGoogle Scholar
• 115  Ochi T, Fujiwara H, Suemori K et al.: Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood113,66–74 (2009).
  Medline CASGoogle Scholar
• 116  Han JF, Zhao TT, Liu HL et al.: Identification of a new HLA-A 0201-restricted cytotoxic T. lymphocyte epitope from CLM28. Cancer Immunol. Immunother.55,1575–1583 (2006)
  Medline CASGoogle Scholar
• 117  Suemori K, Fujiwara H, Ochi T et al.: Identification of an epitope derived from CML 66 a novel tumor-associated antigen expressed broadly in human leukaemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymhocytes. Cancer Sci.99,1414–1419 (2008).
  Medline CASGoogle Scholar
• 118  Chen J, Schmitt A, Bunjes D et al: The receptor for hyaluronic acid-mediated motility induces specific CD8⁺ T cell response in healthy donors and patients with chronic myeloid leukemia after allogenic stem cell transplantation. Int. J. Oncol.30,1119–1127 (2007).
  Medline CASGoogle Scholar
• 119  Hernández-Boluda JC, Bellosillo B, Vela MC, Colomer D, Alvarez-Larrán A, Cervantes F: Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk. Lymphoma46,717–722(2005).
  Medline CASGoogle Scholar
• 120  Zeis M, Siegel S, Wagner A et al.: Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J. Immunol.170,5391–5397 (2003).
  Medline CASGoogle Scholar
• 121  Tschiedel S, Gentilini C, Lange T et al.: Indentification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia22,1542–1550 (2008).
  Medline CASGoogle Scholar
• 122  Andersen MH, Svane IM, Kvistborg P et al.: Immunogenicity of Bcl-2 in patients with cancer. Blood105,728–734 (2004).
  MedlineGoogle Scholar
• 123  Andersen MH, Reker S, Kvistborg P, Becker JC, thor Straten P: Spontaneous immunity against Bcl-xL in cancer patients. J. Immunol.175,2709–2714 (2005).
  Medline CASGoogle Scholar
• 124  Greiner J, Schmitt M, Li L et al.: Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood108,4109–4117 (2006).
  Medline CASGoogle Scholar
• 125  Schmidt SM, Schag K, Müller MR et al.: Induction of adipophillin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res.64,1164–1170 (2004).
  Medline CASGoogle Scholar
• 126  Aqui NA, Vonderheide RH: Survinin as a universal tumor antigen for novel cancer immunotherapy. Cancer Biol. Ther.1888–1889 (2008).
  MedlineGoogle Scholar
• 127  Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disese on imatinib mesylate. Clin. Cancer Res.16,338–347 (2010).
  Medline CASGoogle Scholar